Presentation

Company Profile
Herantis Pharma is a drug development company focusing on disease-modifying treatments for Parkinson’s Disease and other neurodegenerative diseases. The company has one drug candidate in clinical development stage: CDNF for the treatment of Parkinson’s disease and other neurodegenerative diseases. CDNF is a protein naturally present in humans, which has demonstrated promising neuroprotective and neurorestorative activity mediated via several mechanisms relevant to neurodegenerative diseases. Herantis is headquartered in Espoo, Finland, and has been listed on Nasdaq First North Finland since 2014. In December 2019, it also made an IPO on Nasdaq First North Stockholm.

Recent highlights
In March, Herantis announced that the Phase II results from their other clinical programme Lymfactin® came out inconclusive, shifting the company’s focus toward the CDNF programmes and the CNS space. In May, the company announced that a study showing CDNF’s therapeutic effects in alpha-synuclein-based animal models was published online in “Molecular Therapy”. On the same month, the company announced the selection of HER-096 as the preclinical xCDNF candidate.

Outlook
In 2021, Herantis targets to complete the formulation and the pre-clinical studies for the new administration routes for CDNF in Parkinson’s disease and Stroke. At the same time, the company aims to commence the pre-clinical activities for their secondary programme xCDNF before the end of the year.